Local delivery
Our programs are being developed for ocular administration using lipid nanoparticle delivery, concentrating the therapeutic approach at the site of disease.
Retinal vascular therapeutics
Restoring vascular balance in the retina.
Oculibria is developing locally delivered therapeutics for diabetic retinopathy. Our programs are designed to address pathologic vascular signaling while supporting endothelial stability and retinal vascular health.
Approach
Designed around retinal vascular homeostasis.
Diabetic retinopathy is a disorder of the retinal vascular environment, not simply the presence of a single excess signal. Oculibria is developing a focused therapeutic strategy intended to moderate disease-associated angiogenic activity while supporting vascular integrity.
Responsive control
Therapeutic activity is designed around disease-relevant biology, with the objective of providing biological control that reflects the local vascular state.
Vascular support
Complementary biology is incorporated with the aim of supporting endothelial maturation, vascular integrity and a less leak-prone retinal vasculature.
Disease focus
Diabetic retinopathy is a disease of vascular instability.
As diabetes places sustained stress on the retinal microvasculature, abnormal signaling, endothelial dysfunction and vascular leakage contribute to progressive retinal injury. Oculibria is pursuing a treatment state that addresses both pathologic drive and vascular stability.
The objective is not simply maximal suppression. It is to move diseased retinal vasculature toward a more controlled and stable biological state.
- Indication
- Diabetic retinopathy
- Biology
- Retinal vascular homeostasis
- Delivery
- Local ocular LNP
- Development
- In vitro
Pipeline
A focused portfolio in retinal vascular disease.
OL-001, OL-002 and OL-003 are research-stage programs being evaluated within Oculibria's ocular therapeutic framework. All three are currently in vitro, with preclinical development planned following successful validation.
Candidate-specific construct and formulation details are intentionally not disclosed while research is ongoing.
Diabetic retinopathy
Retinal vascular therapeuticResearch program
OL-001
In vitro validation
Retinal vascular therapeuticResearch program
OL-002
In vitro validation
Retinal vascular therapeuticResearch program
OL-003
In vitro validation
Current stage: in vitro validation.
Preclinical development is planned following successful experimental validation.